{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:10:19Z","timestamp":1791414619423,"version":"4.3.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,3,5]],"date-time":"2010-03-05T00:00:00Z","timestamp":1267747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00280-010-1282-4","type":"journal-article","created":{"date-parts":[[2010,3,4]],"date-time":"2010-03-04T15:09:55Z","timestamp":1267715395000},"page":"49-56","source":"Crossref","is-referenced-by-count":64,"title":["DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity"],"prefix":"10.1007","volume":"67","author":[{"given":"Chen Guang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ciccolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Blesius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Bagarry-Liegey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Varoquaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Frances","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafedh","family":"Marouani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Giovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose-Marie","family":"Ferri-Dessens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Chefrour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Favre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Duffaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Zanaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lacarelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,5]]},"reference":[{"key":"1282_CR1","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1200\/JCO.1994.12.12.2648","volume":"12","author":"GP Browman","year":"1994","unstructured":"Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine MN (1994) Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 12:2648\u20132653","journal-title":"J Clin Oncol"},{"key":"1282_CR2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2407-6-28","volume":"6","author":"W Budach","year":"2006","unstructured":"Budach W, Hehr T, Budach V, Belka C, Dietz K (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6:28","journal-title":"BMC Cancer"},{"key":"1282_CR3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3322\/CA.2007.0004","volume":"58","author":"N Choong","year":"2008","unstructured":"Choong N, Vokes E (2008) Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin 58:32\u201353","journal-title":"CA Cancer J Clin"},{"key":"1282_CR4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jjco\/hyn022","volume":"38","author":"D Chua","year":"2008","unstructured":"Chua D, Wei WI, Sham JS, Au GK (2008) Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. Jpn J Clin Oncol 38:244\u2013249","journal-title":"Jpn J Clin Oncol"},{"key":"1282_CR5","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00280-005-0139-8","volume":"58","author":"J Ciccolini","year":"2006","unstructured":"Ciccolini J, Mercier C, Dahan L, Evrard A, Boyer JC, Richard K, Dales JP, Durand A, Milano G, Seitz JF, Lacarelle B (2006) Toxic death-case after capecitabine\u00a0+\u00a0oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine dehydrogenase deficiency. Cancer Chemother Pharmacol 58:272\u2013275","journal-title":"Cancer Chemother Pharmacol"},{"key":"1282_CR6","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/01.ftd.0000245771.82720.c7","volume":"28","author":"J Ciccolini","year":"2006","unstructured":"Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, Richard K, Blanquicett C, Milano G, Blesius A, Durand A, Seitz JF, Favre R, Lacarelle B (2006) A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit 28:678\u2013685","journal-title":"Ther Drug Monit"},{"key":"1282_CR7","first-page":"2039","volume":"4","author":"R Fety","year":"1998","unstructured":"Fety R, Rolland F, Barberi-Heyob M, Hardouin A, Campion L, Conroy T, Merlin JL, Riviere A, Perrocheau G, Etienne MC, Milano G (1998) Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 4:2039\u20132045","journal-title":"Clin Cancer Res"},{"key":"1282_CR8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0360-3016(92)90768-D","volume":"23","author":"JF Fowler","year":"1992","unstructured":"Fowler JF, Lindstrom MJ (1992) Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 23:457\u2013467","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1282_CR9","doi-asserted-by":"crossref","first-page":"8636","DOI":"10.1200\/JCO.2004.00.1990","volume":"23","author":"R Hitt","year":"2005","unstructured":"Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Marti JL, Lobo F, Pastor P, Valenti V, Belon J, Sanchez MA, Chaib C, Pallares C, Anton A, Cervantes A, Paz-Ares L, Cortes-Funes H (2005) Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23:8636\u20138645","journal-title":"J Clin Oncol"},{"key":"1282_CR10","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/annonc\/mdf268","volume":"13","author":"R Hitt","year":"2002","unstructured":"Hitt R, Paz-Ares L, Brandariz A, Castellano D, Pena C, Millan JM, Calvo F, Ortiz de Urbina D, Lopez E, Alvarez-Vicent JJ, Cortes-Funes H (2002) Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial. Ann Oncol 13:1665\u20131673","journal-title":"Ann Oncol"},{"key":"1282_CR11","volume-title":"Genomics and pharmacogenomics in anticancer drug development and clinical response","year":"2009","unstructured":"Innocenti F (ed) (2009) Genomics and pharmacogenomics in anticancer drug development and clinical response. Humana Press, Totowa"},{"key":"1282_CR12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1992.10.2.257","volume":"10","author":"C Jacobs","year":"1992","unstructured":"Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L et al (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:257\u2013263","journal-title":"J Clin Oncol"},{"key":"1282_CR13","first-page":"2006","volume":"5","author":"MR Johnson","year":"1999","unstructured":"Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB (1999) Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5:2006\u20132011","journal-title":"Clin Cancer Res"},{"key":"1282_CR14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330\u2013338","journal-title":"Nat Rev Cancer"},{"key":"1282_CR15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3816\/CCC.2006.n.047","volume":"6","author":"C Mercier","year":"2006","unstructured":"Mercier C, Ciccolini J (2006) Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil\/capecitabine therapy. Clin Colorectal Cancer 6:288\u2013296","journal-title":"Clin Colorectal Cancer"},{"key":"1282_CR16","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/jco.2006.24.18_suppl.2020","volume":"24","author":"C Mercier","year":"2006","unstructured":"Mercier C, Yang C, Ciccolini J, Balti M, Evrard A, Blesius A, Dahan L, Richard K, Seitz J, Lacarelle B, Favre R (2006) Determination of uracil\/UH2 ratio as a potential surrogate for DPD status in cancer patients presenting with severe toxicities during fluoropyrimidine treatment. J Clin Oncol 24:2020 Meeting Abstracts","journal-title":"J Clin Oncol"},{"key":"1282_CR17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1081\/CBI-120002597","volume":"19","author":"G Milano","year":"2002","unstructured":"Milano G, Chamorey AL (2002) Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int 19:177\u2013189","journal-title":"Chronobiol Int"},{"key":"1282_CR18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0163-7258(90)90056-8","volume":"48","author":"WB Parker","year":"1990","unstructured":"Parker WB, Cheng YC (1990) Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48:381\u2013395","journal-title":"Pharmacol Ther"},{"key":"1282_CR19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74\u2013108","journal-title":"CA Cancer J Clin"},{"key":"1282_CR20","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0360-3016(97)00466-5","volume":"39","author":"LJ Peters","year":"1997","unstructured":"Peters LJ, Withers HR (1997) Applying radiobiological principles to combined modality treatment of head and neck cancer\u2013the time factor. Int J Radiat Oncol Biol Phys 39:831\u2013836","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1282_CR21","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","volume":"357","author":"MR Posner","year":"2007","unstructured":"Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705\u20131715","journal-title":"N Engl J Med"},{"key":"1282_CR22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1517\/17425255.1.2.187","volume":"1","author":"PH Roos","year":"2005","unstructured":"Roos PH, Bolt HM (2005) Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1. Expert Opin Drug Metab Toxicol 1:187\u2013202","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1282_CR23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1989.59","volume":"59","author":"J Santini","year":"1989","unstructured":"Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, Schneider M, Demard F (1989) 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59:287\u2013290","journal-title":"Br J Cancer"},{"key":"1282_CR24","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1200\/JCO.1995.13.7.1656","volume":"13","author":"M Schneider","year":"1995","unstructured":"Schneider M, Etienne MC, Milano G, Thyss A, Otto J, Dassonville O, Mobayen H, Saudes L, Guillot T, Demard F (1995) Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. J Clin Oncol 13:1656\u20131662","journal-title":"J Clin Oncol"},{"key":"1282_CR25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.canlet.2007.06.015","volume":"256","author":"PM Specenier","year":"2007","unstructured":"Specenier PM, Vermorken JB (2007) Neoadjuvant chemotherapy in head and neck cancer: should it be revisited? Cancer Lett 256:166\u2013177","journal-title":"Cancer Lett"},{"key":"1282_CR26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1586\/14737140.8.3.375","volume":"8","author":"PM Specenier","year":"2008","unstructured":"Specenier PM, Vermorken JB (2008) Recurrent head and neck cancer: current treatment and future prospects. Expert Rev Anticancer Ther 8:375\u2013391","journal-title":"Expert Rev Anticancer Ther"},{"key":"1282_CR27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0378-4347(95)00228-B","volume":"672","author":"S Sumi","year":"1995","unstructured":"Sumi S, Kidouchi K, Ohba S, Wada Y (1995) Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography. J Chromatogr B Biomed Appl 672:233\u2013239","journal-title":"J Chromatogr B Biomed Appl"},{"key":"1282_CR28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/BF00255288","volume":"16","author":"A Thyss","year":"1986","unstructured":"Thyss A, Milano G, Renee N, Vallicioni J, Schneider M, Demard F (1986) Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 16:64\u201366","journal-title":"Cancer Chemother Pharmacol"},{"key":"1282_CR29","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1200\/JCO.1991.9.11.2027","volume":"9","author":"DL Trump","year":"1991","unstructured":"Trump DL, Egorin MJ, Forrest A, Willson JK, Remick S, Tutsch KD (1991) Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 9:2027\u20132035","journal-title":"J Clin Oncol"},{"key":"1282_CR30","first-page":"1149","volume":"7","author":"AB Kuilenburg van","year":"2001","unstructured":"van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH (2001) Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14\u00a0+\u00a01G\u00a0>\u00a0A mutation causing DPD deficiency. Clin Cancer Res 7:1149\u20131153","journal-title":"Clin Cancer Res"},{"key":"1282_CR31","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","volume":"357","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695\u20131704","journal-title":"N Engl J Med"},{"key":"1282_CR32","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.1996.14.5.1663","volume":"14","author":"EE Vokes","year":"1996","unstructured":"Vokes EE, Mick R, Kies MS, Dolan ME, Malone D, Athanasiadis I, Haraf DJ, Kozloff M, Weichselbaum RR, Ratain MJ (1996) Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol 14:1663\u20131671","journal-title":"J Clin Oncol"},{"key":"1282_CR33","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1200\/JCO.2007.14.9609","volume":"26","author":"CM Walko","year":"2008","unstructured":"Walko CM, McLeod HL (2008) Will we ever be ready for blood level-guided therapy? J Clin Oncol 26:2078\u20132079","journal-title":"J Clin Oncol"},{"key":"1282_CR34","first-page":"439","volume":"80","author":"J Wihlm","year":"1993","unstructured":"Wihlm J, Leveque D, Velten M, Klein T (1993) Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion. Bull Cancer 80:439\u2013445","journal-title":"Bull Cancer"},{"key":"1282_CR35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cncr.21994","volume":"107","author":"FP Worden","year":"2006","unstructured":"Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, Urba SG, Ensley J, Hussain MH (2006) A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. Cancer 107:319\u2013327","journal-title":"Cancer"},{"key":"1282_CR36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","volume":"249","author":"M Boisdron-Celle","year":"2007","unstructured":"Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, Gamelin E (2007) 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 249:271\u2013282","journal-title":"Cancer Lett"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1282-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1282-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1282-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T22:22:35Z","timestamp":1590704555000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1282-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,5]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["1282"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1282-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,5]]}}}